PAVmed (PAVM) Q1 2025 Earnings Call May 15, 2025 08:30 AM ET Company Participants Matt Riley - Director - Investor RelationsLishan Aklog - Chairman and CEODennis McGrath - President & CFO Conference Call Participants Jeremy Pearlman - Equity AnalystEdward Woo - Director of Research & Senior Analyst Operator Good morning and welcome to the PAVmed First Quarter twenty twenty five Business Update Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a que ...

Summary of Mettler-Toledo International (MTD) Conference Call Company Overview - **Company**: Mettler-Toledo International (MTD) - **Date of Conference**: May 14, 2025 - **Speaker**: Sean Vidalia, Chief Financial Officer Key Points Financial Performance - **1Q Results**: MTD reported a 3% growth in underlying business, excluding shipping delays [3][4] - **Lab Business Growth**: Mid single-digit growth, with process analytics business growing just under 10% [3][4] - **Product Inspection**: Grew by 8%, indicating strong execution and new product introductions [4][5] - **Liquid Handling Business**: Experienced slight decline, affected by small biotech and academia sectors [4] Fiscal Year 2025 Guidance - **Tariff Impact**: Adjusted top-line guidance due to trade war uncertainties, with a 2% reduction in EPS guidance [6][8] - **Tariff Costs**: Estimated gross tariff headwind of $115 million annually, translating to a 7% headwind to EPS [11][12] - **China Tariff Changes**: Anticipated benefits from temporary de-escalation of tariffs, with a potential 3.5% EPS benefit [11][16] Market Dynamics - **China Market Outlook**: Initial expectations of low single-digit growth revised to slight decline; however, potential for future growth remains [28][32] - **Emerging Markets**: Growth in Southeast Asia, India, and Eastern Europe, now representing 18% of MTD's business, surpassing China [33][34] - **Academic and Government Sector**: Low single-digit percentage of global business; softness noted in both consumables and instruments [37][39] Biopharma and Process Analytics - **Bioprocessing**: Strong performance in process analytics, particularly with single-use technologies [42][45] - **Life Sciences Exposure**: Comprises about 40% of MTD's business, with a focus on production and QA/QC labs [46] Industrial Sector - **Core Industrial Business**: Represents 25% of MTD's business; guidance for flattish growth due to economic softness [49][50] - **Chemicals Sector**: Noted as softer relative to other end markets, indicating cyclicality [51] Reshoring and Supply Chain - **Reshoring Trends**: Companies are adopting "China plus one" strategies, diversifying supply chains to include emerging markets [35][36] - **Automation Demand**: Increased focus on automated solutions as companies seek productivity amidst rising costs [58][59] Margin Expansion Opportunities - **P&L Levers**: Continuous improvement culture, innovation, and pricing strategies are key to margin expansion [62][64] - **Cash Flow**: Strong cash flow conversion at approximately 100% [65][66] Underappreciated Aspects - **Diversity of Solutions**: MTD's ability to provide solutions across the entire value chain is a significant strength, especially in the context of reshoring [66] Additional Insights - **Market Uncertainty**: Ongoing uncertainties in the market, particularly regarding China, will be closely monitored for future guidance updates [27][29] - **Long-term Growth**: Despite current challenges, MTD remains optimistic about future growth opportunities in various sectors [32][33]

Summary of Guardant Health (GH) 2025 Conference Call Company Overview - **Company**: Guardant Health (GH) - **Event**: 2025 Conference on May 14, 2025 - **Speakers**: Helmio Touki (Chairman, Co-Founder, CEO), Amir Aliy Talasaz (Co-Founder, Co-CEO), Mike Bell (CFO) Key Points Industry and Product Performance - **Shield Test**: - 9,000 tests conducted in Q1, exceeding expectations [5] - Volume guidance raised to 52,000 - 58,000 tests for the year, indicating strong launch performance [7][9] - Anticipated revenue of $40 million to $45 million from Shield, potentially one of the largest diagnostic launches [9] - Cost per test reduced from over $1,000 to below $600, with a goal of reaching $200 per test by achieving higher volumes [15][17] - **Shield V2**: - New algorithm developed to improve sensitivity for colorectal cancer detection [19] - Expected FDA submission and potential approval by year-end [20] - **REVEAL Test**: - Positive reimbursement decision for colorectal cancer surveillance, leading to increased volumes [25] - Transitioned from gross margin negative to positive, with ASP over $600 and COGS around $500 [30][31] - **Guardant360 (G360)**: - ASP increased from $2,700 to $3,100, with further growth potential through payer negotiations [41] - Significant growth driven by the launch of a smart liquid biopsy platform [39] Financial Guidance and Profitability - **Financial Outlook**: - Screening business expected to incur a net burn of $200 million over the next two years, with a path to breakeven by 2028 [61][63] - Other segments, including therapy selection and biopharma, are already profitable, contributing to overall financial health [62] Market Position and Strategy - **Comprehensive Portfolio**: - Guardant is positioned uniquely with offerings across screening, MRD, and treatment selection, differentiating itself from competitors [65] - Anticipated integration of services to simplify the ordering process for oncologists [54] - **Future Growth**: - Plans to expand sales force to 700 representatives to enhance nationwide coverage [13] - Continuous investment in automation and workflow efficiencies to further reduce costs [16] Additional Insights - **Multi-Cancer Detection**: - Shield designed as a multi-cancer detection platform, with potential to expand indications beyond colorectal cancer [21] - Selected by the National Cancer Institute for a multi-cancer detection trial [22] - **Clinical Utility and Research**: - Ongoing studies and trials expected to provide additional data readouts, enhancing the clinical utility of tests [35] This summary encapsulates the key insights and developments discussed during the Guardant Health conference call, highlighting the company's strategic direction, product performance, and financial outlook.

Core Insights - Biodesix, Inc. has been recognized as a Colorado Top Workplaces 2025 Winner, highlighting its commitment to a people-first organizational culture [1] - This recognition is based on employee feedback collected through a third-party survey conducted by Energage, which measures various aspects of the employee experience [2] - This marks the second consecutive year that Biodesix has received such recognition, following the Inc. Magazine 2024 Best Workplaces award [3] Company Overview - Biodesix is a leading diagnostic solutions company focused on improving clinical care and outcomes for patients, particularly those with lung disease [4] - The company offers diagnostic tests that support clinical decisions and expedite personalized care, as well as development services for biopharmaceutical and life sciences companies [4] Employee Engagement - The Top Workplaces award is based on themes such as respect, support, growth opportunities, and empowerment within the workplace [2][4] - The CEO of Biodesix emphasized the importance of employee contributions to the company's high-performing culture and commitment to excellence [3] About Energage - Energage is a company that specializes in turning employee feedback into actionable business intelligence and employer recognition through the Top Workplaces program [5] - The organization has a rich history of culture research, having surveyed over 27 million employees across more than 70,000 organizations [5]

Core Insights - MDxHealth reported a year-over-year revenue increase of 22% to $24.3 million for Q1 2025, marking the 16th consecutive quarter of revenue growth of 20% or more [1][2][6] - The company expects to achieve adjusted EBITDA profitability in Q2 2025 and has reiterated its revenue guidance for 2025 at $108-110 million [2][9] Financial Performance - Revenue for Q1 2025 was $24.3 million, up from $19.8 million in Q1 2024, representing a 22% increase [4][6] - Gross profit increased by 29% to $15.5 million, with gross margins improving to 63.8% from 60.8% year-over-year [7][9] - Operating expenses rose by 8% to $20.1 million, primarily due to increased clinical trial expenses and stock-based compensation [7][9] - The net loss for Q1 2025 was $9.2 million, an 8% increase from $8.5 million in the prior year, largely due to non-cash fair value adjustments [8][9] - Adjusted EBITDA improved by 71% to a loss of $1.3 million compared to a loss of $4.5 million in Q1 2024 [10][23] Operational Highlights - Tissue-based tests accounted for 85% of total revenue in Q1 2025, up from 79% in Q1 2024 [6] - Test volumes for tissue-based tests increased by 41% to 12,677, while liquid-based test volumes rose by 9% to 11,530 [9] - The company ended Q1 2025 with cash and cash equivalents of $65.7 million [10][22] Subsequent Events - On April 29, 2025, MDxHealth made a $28.0 million earnout payment to Exact Sciences, which would adjust the pro-forma cash balance to $37.7 million as of March 31, 2025 [11]

Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City. The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will ...

Core Viewpoint - Lucid Diagnostics Inc. has secured capital to extend its operational runway significantly, positioning the company to capitalize on upcoming reimbursement milestones and accelerate commercialization efforts for its EsoGuard product [4][6]. Business Highlights - The company is expanding cash-pay and contracted programs targeting concierge medicine practices and self-insured employers, while also gaining traction with regional commercial insurers for EsoGuard coverage [4]. - A partnership with a major health system has been established to launch a comprehensive EsoGuard esophageal precancer testing program, enhancing access for at-risk patients [6]. - The company has launched the "Embrace the Future" campaign to promote its EsoCheck® Cell Collection Device, which features innovative technology compared to traditional methods [6]. - A National Cancer Institute-sponsored study has shown that EsoGuard effectively detects esophageal precancer in at-risk patients without GERD, potentially increasing market opportunity by up to 70% [6]. Financial Results - For the three months ended March 31, 2025, Lucid processed 3,034 EsoGuard tests and recognized $0.8 million in revenue from EsoGuard [6]. - The company reported operating expenses of approximately $13.3 million, including $1.0 million in stock-based compensation, leading to a GAAP net loss of approximately $36.0 million or $(0.52) per share [6][9]. - The non-GAAP adjusted loss for the same period was approximately $11.2 million or $(0.16) per share [7][11]. - As of March 31, 2025, Lucid had cash and cash equivalents of $25.2 million, an increase from $22.4 million as of December 31, 2024, and completed a public offering for net proceeds of $16.1 million [10].

Company Overview - Thermo Fisher Scientific Inc. is represented by Marc Casper, the Chairman, President, and CEO, at the BofA Securities 2025 Healthcare Conference [1][2]. Industry Insights - The company is optimistic about the recovery of end-markets entering 2025, indicating a focus on raising earnings growth ambitions as market conditions improve, although they are not yet fully normalized [4]. - The first quarter of 2025 is highlighted as a period of significant developments in the macro and policy landscape, which has implications for the tools sector [3]. Conference Context - The conference serves as a platform for discussing the current state of the tools sector amidst turbulent times, with an emphasis on the importance of the event for stakeholders [3]. - The participation of key executives and the focus on industry trends reflect the company's commitment to engaging with investors and addressing market dynamics [1][3].

Financial Data and Key Metrics Changes - Total revenue for the first quarter was $18 million, representing a 21% increase year over year [24] - Lung diagnostic testing revenue was $16.3 million, with a 18% growth in revenue and 16% growth in test volumes [24] - Gross margin improved to 79.4%, up from 78.6% in the prior year [25] - Net loss for the quarter was $11.1 million, an 18% improvement year over year [26] - Adjusted EBITDA loss was $6.2 million, an 11% improvement year over year [26] Business Line Data and Key Metrics Changes - Lung diagnostics revenue grew 18%, marking the sixteenth consecutive quarter of over 15% year-over-year growth [6] - Development services revenue was $1.7 million, a 61% increase over the previous year [24] - The pipeline for development services ended the quarter with $10.9 million under contract, a 21% increase year over year [25] Market Data and Key Metrics Changes - The company is focusing on expanding its presence in the primary care market, which is critical for lung nodule management [8][11] - Digital ordering capabilities increased by 58% over the last year, with customer retention for digital users being 40% higher [10] Company Strategy and Development Direction - The company aims to achieve positive adjusted EBITDA by the fourth quarter of 2025 while focusing on revenue growth and operational efficiencies [5][28] - A shift to a territory-based sales approach has been implemented to enhance market access and patient identification [11][13] - The company is exploring the integration of AI and radiomics into its diagnostic offerings to improve clinical workflows [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue growth despite current hiring delays and operational challenges [28][47] - The company anticipates an acceleration of growth in the second half of 2025 as the sales team expands [27] - Management highlighted the importance of maintaining operational efficiencies and cost control to reach profitability [26][82] Other Important Information - The company has been recognized as a top workplace for the second consecutive year, reflecting its strong team culture [30] - A research and development day is planned for the fall to provide further insights into the company's pipeline and progress [22] Q&A Session Summary Question: Can you elaborate on the sales force changes and hiring challenges? - Management noted that the shift from pulmonology to primary care required a different hiring profile, which took longer than anticipated [34][35] Question: What is the outlook for Q2 and the rest of the year? - The company expects to have 70 to 75 sales reps in Q2, with plans to increase to 95 by Q4 [41] Question: How are primary care physicians responding to the technology? - Early feedback indicates that primary care physicians are recognizing the value of the diagnostic tests, with a focus on identifying high-risk patients [44][66] Question: What is the impact of the $10 million loan on capital needs? - The additional capital provides more flexibility and confidence in achieving breakeven, supporting both commercial expansion and pipeline activities [47][48] Question: How does the sales force configuration affect territory management? - The company is strategically assigning sales reps based on test volumes and geographic considerations to maximize market access [96]

Biodesix (BDSX) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Please be advised that today's conference is being recorded. I would now like to hand the conference over to Chris Brenzi. You may begin. Speaker1 Thank you, operator, and good afternoon, everyone. Today, Biodesix released results from the first quarter of twenty twenty five. Leading the call today will be Scott Hutton, Chief Executive Officer. He is joined by Robin Harpurkawi, Chief Financial Officer. An audio recording of today's call ...